The U.S. mRNA synthesis raw materials market size is anticipated to reach USD 976.2 million by 2030 and is growing at a CAGR of 2.93% from 2024 to 2030. The major factors driving the market include growing academic & industrial interest in mRNA technology, advantages of mRNA vaccines, and increasing funding for mRNA research.
The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.
Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.
However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.
The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.
Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.
However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.
U.S. mRNA Synthesis Raw Materials Market Report Highlights
- Capping agents dominated the type segment with the largest revenue share of 41.02% in 2023. Capping agents function as binding molecules or stabilizers, preventing steric hindrance or agglomeration. Hence, these key functions of capping agents in mRNA synthesis are driving the segment
- Based on the application, vaccine production held the largest revenue market share of 83.86% in 2023. The rising prevalence of chronic diseases, such as cancer, respiratory disorders, cardiac diseases, CKD, and many others, is encouraging scientists to discover novel as well as more effective vaccines using mRNA technology
- Based on end-use, biopharmaceutical & pharmaceutical companies dominated the segment with a revenue share of 49.56% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the emerging companies in the market entering several collaborations to enhance their mRNA synthesis raw materials offerings
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. MRNA Synthesis Raw Material Market Variables, Trends, & Scope
Chapter 4. U.S. MRNA Synthesis Raw Material Market: Type Estimates & Trend Analysis
Chapter 5. U.S. MRNA Synthesis Raw Material Market: Application Estimates & Trend Analysis
Chapter 6. U.S. MRNA Synthesis Raw Material Market: End-use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Jena Bioscience GmbH
- Merck KGaA
- Yeasen Biotechnology (Shanghai) Co., Ltd
- BOC Sciences
- Thermo Fisher Scientific, Inc.
- Maravai LifeSciences
- New England Biolabs
- Creative Biogene
- HONGENE
- Evonik Industries AG
- GENEVANT SCIENCES CORPORATION
Methodology
LOADING...
![mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029 - Product Image](http://www.researchandmarkets.com/product_images/12700/12700988_60px_jpg/mrna_synthesis_and_manufacturing_market.jpg)
